BioArctic AB
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as disease modifiers. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies. BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 1992
About Us
Our main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Today there are no treatments that can stop or slow down the progression of these diseases.
We collaborate with research groups at universities and hospitals, and with our global research and development partners Eisai and AbbVie.
BioArctic contracts also external companies to a large extent for pharmacology, toxicology studies, process development, the manufacturing of drug substances and the performance of clinical trials.
Groundbreaking discoveriesBioArctic is a Swedish research oriented biopharma company. The company was founded in 2003 by Professor Lars Lannfelt and Dr. Pär Gellerfors to develop important breakthrough discoveries made by Professor Lannfelt regarding Alzheimer’s disease. These discoveries – the Swedish mutation and the Arctic mutation – have attracted much attention internationally and explain the central role of amyloid-beta in Alzheimer’s disease, which has led to the development of new treatment strategies.
BioArctic has developed a proprietary technology platform that has proven to be successful when the company’s first drug candidate antibody BAN2401 for Alzheimer´s disease was developed.
The company’s technology is now also used for other disorders of the Central Nervous System such as Parkinson’s disease (drug candidate antibody ABBV-0805) and also for related diagnostics and technology.
Strengths and success factorsBioArctic´s success is built on vast scientific competence and highly skilled employees who thrive and deliver with great quality.
At BioArctic we are proud of our strengths, which we consider to be important success factors in our ambition to improve the quality of life for patients with diseases affecting the Central Nervous System.
BioArctic’s strengths include:
- Highly qualified staff with proven ability to develop drugs
- An innovative project portfolio consisting of differentiated first generation disease modifying drug candidates for neurodegenerative diseases, as well as related diagnostics and technology
- Strategic collaborations and partnerships with the global pharma companies Eisai and AbbVie and funding from the EU’s Horizon2020 that validate the ability of the research organization and the potential of the drug candidates
- An attractive combination of fully financed partner projects with significant market potential and innovative in-house projects with significant outlicensing potential
- A strong intellectual property rights portfolio.
Vision, Mission and Business Concept
Vision
Our research generates innovative medicines that improve life for patients with disorders in the central nervous system.
Mission
Together we generate the medicines of the future for patients with central nervous system disorders.
Business concept
BioArctic is a Swedish biopharma company that develops new drugs based on groundbreaking research for patients with central nervous system disorders. For a global market, the aim is to generate transformative medicines that can stop or slow down the progression of diseases, principally Alzheimer’s and Parkinson’s diseases.
Culture and Values
In order to accomplish our vision and mission BioArctic encourages a strong culture of curiosity and innovation among our employees and partners. We also strive to be an attractive and leading partner in our research areas for research groups at universities, pharma companies and in health care.
Our core values are our guiding lightOur core values guide our decision making, define our beliefs and foster the BioArctic culture.
Our strong dedication to the company values helps us execute the strategy in line with our vision and mission.
- Respect – we act respectfully
- Engagement – we are highly engaged in everything we do
- Collaboration – we collaborate to achieve our common goals
- Responsibility – we act responsibly to deliver on time and with high quality and share our knowledge with others
Objective and Strategy
BioArctic’s goal is to build an innovative and competitive portfolio of product candidates, diagnostics and technology for the indications in which the Company is active, partly through in-house research and development, partly through research collaborations with strategic partners.
Our research and development work is proceeding in line with this strategy.
Important elements of BioArctic’s strategy are:
- Further development and expand the portfolio of innovative product candidates in attractive indication areas with great unmet medical needs
- Accelerate the development of the portfolio of diagnostic methods and technologies related to the drug development
- Evaluate opportunities for further strategic collaborations and partnerships for the development and commercialization of product candidates
- Build a sales organization in selected markets for own marketing and sales of approved products
- Promote an attractive environment for research and development and human capital.
Organization
BioArctic is organized to have all the necessary competences and knowledge needed to be an innovative, world-class biopharma company. The organization consists of highly educated and research-oriented employees and consultants with vast experience of bringing drugs from idea to market.
BioArctic’s Senior management and Board of directors consist of balanced teams with competence and experience from leading academic positions as well as extensive industrial and business background.
BioArctic’s laboratories and headquarters are located in central Stockholm, Sweden, where approximately 60 employees and consultants are working. In order to conduct efficient operations with a relatively small organization, BioArctic engages key consultants for specific assignments and for tasks in competence areas that the company lacks or only has periodic need for.